GENE ONLINE|News &
Opinion
Blog

2023-12-20| R&D

Pioneering Vaccine Offers Hope for Affordable Cholesterol Management

by Sinead Huang
Share To

Cardiovascular disease (CVD) remains the primary cause of global mortality, claiming nearly 19 million lives in 2020. Elevated levels of low-density lipoprotein cholesterol (LDL-C) significantly contribute to atherosclerotic cardiovascular disease (ASCVD). While statins are widely prescribed, their varying effectiveness and potential adverse effects have led to the quest for alternative lipid-lowering therapies.Recently, researchers at The University of New Mexico School of Medicine have developed a PCSK9-targeting vaccine using virus-like particles, showing efficacy in reducing cholesterol levels in animal models.

Related article: FDA Extends Approval Of Regeneron’s Evkeeza For Inherited High Cholesterol

PCSK9 Inhibitors – A Breakthrough but Costly Solution

Protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, including monoclonal antibodies and siRNA-based therapies, have emerged as potent options to reduce LDL-C. FDA-approved therapies like evolocumab and alirocumab showcase efficacy but come with a hefty price tag, raising concerns about cost-effectiveness. These inhibitors, often used in conjunction with statins, are primarily employed for secondary prevention in cases where statin monotherapy falls short.

Novel VLP Vaccine – An Affordable and Efficient Alternative 

Researchers at The University of New Mexico School of Medicine have introduced a groundbreaking vaccine targeting PCSK9. Utilizing virus-like particles (VLPs), the vaccine displays specific PCSK9 peptides, inducing robust anti-PCSK9 antibody responses. Unlike traditional immunological challenges related to self-antigens, VLP-based vaccines efficiently overcome these obstacles. The cost-effective production of vaccines, coupled with their potential for fewer doses, enhances accessibility and patient compliance. The engineered VLP-based vaccine demonstrates efficacy in reducing total cholesterol levels in various animal models, offering a promising avenue for lowering LDL-C without the need for frequent statin administration.

Future Prospects and Global Impact

As the research progresses, the VLP-based vaccine targeting PCSK9 holds immense potential for revolutionizing cholesterol management. The ability to lower LDL-C levels without the frequent administration of statins could mark a significant advancement in cardiovascular care. With an estimated cost per dose under $100, the vaccine’s affordability and global applicability could address the economic constraints associated with current PCSK9 inhibitors. The ongoing efforts to move into vaccine manufacturing and clinical trials signify a ten-year timeline for potential human use, presenting an optimistic outlook for a cost-effective and efficient solution to combat high cholesterol levels globally.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Innovent’s PCSK-9 Antibody Meets Primary Endpoints in Two Phase 3 Studies
2022-02-18
Verve Raises $94M in Series B, Aims to Disrupt Cardiology Market with ‘Once-and-Done’ Gene Editing Therapies
2021-01-21
AstraZeneca Sells its Cholesterol Drug to German Pharma
2020-12-03
LATEST
An Interview with the Inventor of HPV Vaccine, Ian Frazer, Building a Firewall for Public Health
2024-02-29
Taiwan’s Drug Price Adjustments: Balancing Cost and Availability
2024-02-28
Neomorph Links Together With Novo Nordisk in a $1.46 Billion Molecular Glue Partnership Deal
2024-02-27
Breakthrough Study Shows Anti-IgE Antibody Safeguards Children with Multiple Food Allergies
2024-02-27
Cortisol: New Discoveries on its Impact Across Health, Culture, and Evolution
2024-02-26
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
2024-02-21
EVENT
Scroll to Top